317 related articles for article (PubMed ID: 32902661)
1. Nonsuspicious prebiopsy multiparametric MRI: is prostate biopsy still necessary?
Anastay V; Gondran-Tellier B; McManus R; Delonca R; Akiki A; Gaillet S; Delaporte V; Andre M; Daniel L; Karsenty G; Lechevallier E; Boissier R; Baboudjian M
Abdom Radiol (NY); 2020 Dec; 45(12):4160-4165. PubMed ID: 32902661
[TBL] [Abstract][Full Text] [Related]
2. Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-naïve Men with Elevated Prostate-specific Antigen: A Large Prospective Multicenter Clinical Study.
van der Leest M; Cornel E; Israël B; Hendriks R; Padhani AR; Hoogenboom M; Zamecnik P; Bakker D; Setiasti AY; Veltman J; van den Hout H; van der Lelij H; van Oort I; Klaver S; Debruyne F; Sedelaar M; Hannink G; Rovers M; Hulsbergen-van de Kaa C; Barentsz JO
Eur Urol; 2019 Apr; 75(4):570-578. PubMed ID: 30477981
[TBL] [Abstract][Full Text] [Related]
3. The "Is mpMRI Enough" or IMRIE Study: A Multicentre Evaluation of Prebiopsy Multiparametric Magnetic Resonance Imaging Compared with Biopsy.
Stonier T; Simson N; Shah T; Lobo N; Amer T; Lee SM; Bass E; Chau E; Grey A; McCartan N; Acher P; Ahmad I; Arumainayagam N; Brown D; Chapman A; Elf D; Hartington T; Ibrahim I; Leung H; Liyanage S; Lovegrove C; Malthouse T; Mateen B; Mistry K; Morrison I; Nalagatla S; Persad R; Pope A; Sokhi H; Syed H; Tadtayev S; Tharmaratnam M; Qteishat A; Miah S; Emberton M; Moore C; Walton T; Eddy B; Ahmed HU
Eur Urol Focus; 2021 Sep; 7(5):1027-1034. PubMed ID: 33046412
[TBL] [Abstract][Full Text] [Related]
4. Clinically Significant Prostate Cancer Detection After a Negative Prebiopsy MRI Examination: Comparison of Biparametric Versus Multiparametric MRI.
Gan JM; Kikano EG; Smith DA; Rao S; Podury R; Wang M; Durieux JC; Paspulati RM; Ponsky L; Ramaiya NH; Tirumani SH
AJR Am J Roentgenol; 2022 May; 218(5):859-866. PubMed ID: 34817189
[No Abstract] [Full Text] [Related]
5. How to make clinical decisions to avoid unnecessary prostate screening in biopsy-naïve men with PI-RADs v2 score ≤ 3?
Zhang Y; Zeng N; Zhang F; Huang Y; Tian Y
Int J Clin Oncol; 2020 Jan; 25(1):175-186. PubMed ID: 31473884
[TBL] [Abstract][Full Text] [Related]
6. The role of prostate-specific antigen density and negative multiparametric magnetic resonance imaging in excluding prostate cancer for biopsy-naïve men: clinical outcomes from a high-volume center in China.
Zhang CC; Tu X; Lin TH; Cai DM; Yang L; Nie L; Qiu S; Liu ZH; Jin K; Li JK; Xiong XY; Yang L; Wei Q
Asian J Androl; 2022; 24(6):615-619. PubMed ID: 35532555
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancer detection rate in men undergoing transperineal template-guided saturation and targeted prostate biopsy.
Kaufmann B; Saba K; Schmidli TS; Stutz S; Bissig L; Britschgi AJ; Schaeren E; Gu A; Langenegger N; Sulser T; Eberli D; Keller EX; Hermanns T; Poyet C
Prostate; 2022 Feb; 82(3):388-396. PubMed ID: 34914121
[TBL] [Abstract][Full Text] [Related]
8. MRI combined with PSA density in detecting clinically significant prostate cancer in patients with PSA serum levels of 4∼10ng/mL: Biparametric versus multiparametric MRI.
Han C; Liu S; Qin XB; Ma S; Zhu LN; Wang XY
Diagn Interv Imaging; 2020 Apr; 101(4):235-244. PubMed ID: 32063483
[TBL] [Abstract][Full Text] [Related]
9. The Use of Multiparametric Magnetic Resonance Imaging for Follow-up of Patients Included in Active Surveillance Protocol. Can PSA Density Discriminate Patients at Different Risk of Reclassification?
Roscigno M; Stabile A; Lughezzani G; Pepe P; Galosi AB; Naselli A; Naspro R; Nicolai M; La Croce G; Aljoulani M; Perugini G; Guazzoni G; Montorsi F; Balzarini L; Sironi S; Da Pozzo LF
Clin Genitourin Cancer; 2020 Dec; 18(6):e698-e704. PubMed ID: 32493676
[TBL] [Abstract][Full Text] [Related]
10. Combining clinical parameters and multiparametric magnetic resonance imaging to stratify biopsy-naïve men for an optimum diagnostic strategy with prostate-specific antigen 4 ng ml
Zhang CC; Tu X; Lin TH; Cai DM; Yang L; Qiu S; Liu ZH; Yang L; Wei Q
Asian J Androl; 2023; 25(4):492-498. PubMed ID: 36571328
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of prostate cancer identified by transperineal standard template biopsy in men with nonsuspicious multiparametric magnetic resonance imaging.
Dahl DM; Wu S; Lin SX; Hu M; Barney AA; Kim MM; Cornejo KM; Harisinghani MG; Feldman AS; Wu CL
Urol Oncol; 2024 Feb; 42(2):28.e21-28.e28. PubMed ID: 38182499
[TBL] [Abstract][Full Text] [Related]
12. Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in the Detection of Clinically Significant Prostate Cancer in the Prostate Imaging Reporting and Data System Era: A Systematic Review and Meta-analysis.
Sathianathen NJ; Omer A; Harriss E; Davies L; Kasivisvanathan V; Punwani S; Moore CM; Kastner C; Barrett T; Van Den Bergh RC; Eddy BA; Gleeson F; Macpherson R; Bryant RJ; Catto JWF; Murphy DG; Hamdy FC; Ahmed HU; Lamb AD
Eur Urol; 2020 Sep; 78(3):402-414. PubMed ID: 32444265
[TBL] [Abstract][Full Text] [Related]
13. What Is the Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer at Biopsy? A Systematic Review and Meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel.
Moldovan PC; Van den Broeck T; Sylvester R; Marconi L; Bellmunt J; van den Bergh RCN; Bolla M; Briers E; Cumberbatch MG; Fossati N; Gross T; Henry AM; Joniau S; van der Kwast TH; Matveev VB; van der Poel HG; De Santis M; Schoots IG; Wiegel T; Yuan CY; Cornford P; Mottet N; Lam TB; Rouvière O
Eur Urol; 2017 Aug; 72(2):250-266. PubMed ID: 28336078
[TBL] [Abstract][Full Text] [Related]
14. Prebiopsy multiparametric MRI and PI-RADS version 2.0 for differentiating histologically benign prostate disease from prostate cancer in biopsies: A retrospective single-center comparison.
Tosun M; Uslu H
Clin Imaging; 2021 Oct; 78():98-103. PubMed ID: 33773450
[TBL] [Abstract][Full Text] [Related]
15. How to optimize follow-up in patients with a suspicious multiparametric MRI and a subsequent negative targeted prostate biopsy. Results from a large, single-institution series.
Barletta F; Stabile A; Mazzone E; Brembilla G; Sorce G; Pellegrino F; Scuderi S; Cannoletta D; Cirulli GO; Cucchiara V; Gandaglia G; De Cobelli F; Montorsi F; Briganti A
Urol Oncol; 2022 Mar; 40(3):103.e17-103.e24. PubMed ID: 34688534
[TBL] [Abstract][Full Text] [Related]
16. Who with suspected prostate cancer can benefit from Proclarix after multiparametric magnetic resonance imaging?
Morote J; Campistol M; Regis L; Celma A; de Torres I; Semidey ME; Roche S; Mast R; Santamaria A; Planas J; Trilla E
Int J Biol Markers; 2022 Jun; 37(2):218-223. PubMed ID: 35200058
[TBL] [Abstract][Full Text] [Related]
17. 3-T Multiparametric MRI Followed by In-Bore MR-Guided Biopsy for Detecting Clinically Significant Prostate Cancer After Prior Negative Transrectal Ultrasound-Guided Biopsy.
Hosseiny M; Shakeri S; Felker ER; Lu D; Sayre J; Ahuja P; Raman SS
AJR Am J Roentgenol; 2020 Sep; 215(3):660-666. PubMed ID: 32755166
[No Abstract] [Full Text] [Related]
18. Diagnostic Accuracy of Single-plane Biparametric and Multiparametric Magnetic Resonance Imaging in Prostate Cancer: A Randomized Noninferiority Trial in Biopsy-naïve Men.
Russo F; Mazzetti S; Regge D; Ambrosini I; Giannini V; Manfredi M; De Luca S; Bollito E; Porpiglia F
Eur Urol Oncol; 2021 Dec; 4(6):855-862. PubMed ID: 33893066
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Cancer Detection Rates Between TRUS-Guided Biopsy and MRI-Targeted Biopsy According to PSA Level in Biopsy-Naive Patients: A Propensity Score Matching Analysis.
Choi YH; Kang MY; Sung HH; Jeon HG; Chang Jeong B; Seo SI; Jeon SS; Kim CK; Park BK; Lee HM
Clin Genitourin Cancer; 2019 Feb; 17(1):e19-e25. PubMed ID: 30415878
[TBL] [Abstract][Full Text] [Related]
20. Association Between Prostate Imaging Reporting and Data System (PI-RADS) Score for the Index Lesion and Multifocal, Clinically Significant Prostate Cancer.
Stabile A; Dell'Oglio P; De Cobelli F; Esposito A; Gandaglia G; Fossati N; Brembilla G; Cristel G; Cardone G; Deho' F; Losa A; Suardi N; Gaboardi F; Del Maschio A; Montorsi F; Briganti A
Eur Urol Oncol; 2018 May; 1(1):29-36. PubMed ID: 31100225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
